A2 Refereed review article in a scientific journal
Complement System in Cutaneous Squamous Cell Carcinoma
Authors: Pilvi Riihilä, Liisa Nissinen, Jaakko Knuutila, Pegah Rahmati Nezhad, Kristina Viiklepp, Veli-Matti Kähäri
Publisher: MDPI
Publication year: 2019
Journal: International Journal of Molecular Sciences
Journal acronym: INT J MOL SCI
Article number: ARTN 3550
Volume: 20
Issue: 14
Number of pages: 21
ISSN: 1661-6596
eISSN: 1422-0067
DOI: https://doi.org/10.3390/ijms20143550
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/42260930
Abstract
Epidermal keratinocyte-derived cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer with high mortality rates in the advanced stage. Chronic inflammation is a recognized risk factor for cSCC progression and the complement system, as a part of innate immunity, belongs to the microenvironment of tumors. The complement system is a double-edged sword in cancer, since complement activation is involved in anti-tumor cytotoxicity and immune responses, but it also promotes cancer progression directly and indirectly. Recently, the role of several complement components and inhibitors in the regulation of progression of cSCC has been shown. In this review, we will discuss the role of complement system components and inhibitors as biomarkers and potential new targets for therapeutic intervention in cSCC.
Epidermal keratinocyte-derived cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer with high mortality rates in the advanced stage. Chronic inflammation is a recognized risk factor for cSCC progression and the complement system, as a part of innate immunity, belongs to the microenvironment of tumors. The complement system is a double-edged sword in cancer, since complement activation is involved in anti-tumor cytotoxicity and immune responses, but it also promotes cancer progression directly and indirectly. Recently, the role of several complement components and inhibitors in the regulation of progression of cSCC has been shown. In this review, we will discuss the role of complement system components and inhibitors as biomarkers and potential new targets for therapeutic intervention in cSCC.
Downloadable publication This is an electronic reprint of the original article. |  |
UTU Research Portal